H Edward Fleming's most recent trade in Upstream Bio Inc. was a trade of 17,096 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 10, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Upstream Bio Inc. | Fleming H. Edward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
CRISPR Therapeutics AG | H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
CRISPR Therapeutics AG | H Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
CRISPR Therapeutics AG | H Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |